Page last updated: 2024-12-05

1,4-dihydroxyanthraquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,4-Dihydroxyanthraquinone, also known as quinizarin, is a red organic compound with the formula C14H8O4. It is a derivative of anthraquinone, with hydroxyl groups at positions 1 and 4. Quinizarin is a valuable synthetic dye and intermediate for the production of other dyes. It is also used as a reagent in chemical synthesis and as a fluorescent probe.
Quinizarin is synthesized by the reaction of phthalic anhydride with hydroquinone in the presence of sulfuric acid. It can also be synthesized by the oxidation of 1,4-dihydroxyanthracene.
Quinizarin exhibits fluorescence properties, making it useful as a fluorescent probe in various applications. Its strong color also makes it suitable as a dye for textiles, paints, and other materials.
Quinizarin has been investigated for its potential biological activities. Studies have suggested that it may possess antioxidant, anti-inflammatory, and anticancer properties. However, further research is needed to determine its safety and efficacy for therapeutic use.
The importance of quinizarin lies in its versatility as a synthetic dye, a reagent, a fluorescent probe, and a potential therapeutic agent. Its unique properties make it an interesting subject of research in various fields, including chemistry, materials science, and medicine.'
```

1,4-dihydroxyanthraquinone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

quinizarin : A dihydroxyanthraquinone having the two hydroxy substituents at the 1- and 4-positions; formally derived from anthraquinone by replacement of two hydrogen atoms by hydroxy groups [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6688
CHEMBL ID17594
CHEBI ID37487
SCHEMBL ID160038
SCHEMBL ID2639287
MeSH IDM0107254

Synonyms (94)

Synonym
ccris 3524
1,4-dioxyanthraquinone [russian]
einecs 201-368-7
1,4-doa [russian]
1,4-dihydroxy-9,10-anthracenedione
hsdb 5242
nsc 646569
nsc 15367
1,4-dihydroxyanthrachinon [czech]
ai3-17616
ci 58050
1,4-dihydroxy-anthracene-9,10-dione
anthraquinone, 1,4-dihydroxy-
9,10-anthracenedione, 1,4-dihydroxy-
9, 1,4-dihydroxy-
c.i. 58050
nsc40899
solvent orange 86
1,4-dihydroxyanthrachinon
1,4-dihydroxyanthraquinone
nsc15367
smoke orange r
1,4-dioxyanthraquinone
chinizarin
macrolex orange gg
quinizarine
nsc-40899
1,4-doa
wln: l c666 bv ivj dq gq
nsc-15367
1,4-dihydroxyanthra-9,10-quinone
CHEBI:37487 ,
1,4-dihydroxy-9,10-anthraquinone
MEGXP0_001867
ACON1_000101
nsc-646569
nsc646569
quinizarin
81-64-1
1,4-dihydroxy-9,10-anthracene-dione
1,4-dihydroxyanthracene-9,10-dione
inchi=1/c14h8o4/c15-9-5-6-10(16)12-11(9)13(17)7-3-1-2-4-8(7)14(12)18/h1-6,15-16
SR-01000637713-1
quinizarin, 96%
nsc229036
nsc-229036
NCI60_001089
NCGC00160196-01
NCGC00160196-02
STK264108
AC-11267
bdbm50240382
D0243
1,4-dihydroxy-anthraquinone
1,4 dihydroxy-anthraquinone
CHEMBL17594 ,
FT-0657575
A840176
AE-641/02529036
AKOS001595052
unii-8s496zv3cs
ec 201-368-7
8s496zv3cs ,
cas-81-64-1
tox21_302041
dtxcid6024464
NCGC00255951-01
dtxsid8044464 ,
BBL010354
CCG-48149
F1565-0160
1,4-dihydroxy-9,10-anthracenedione [hsdb]
dihydroxyanthraquinone, 1,4-
quinizarin [mi]
SCHEMBL160038
SCHEMBL2639287
103220-12-8
W-104202
1,4-dihydroxyanthra-9,10-quinone #
mfcd00001209
SR-01000108129-1
sr-01000108129
9,10-dihydroxy-1,4-anthraquinone
1,4-dihydroxy-9,10-dihydroanthracene-9,10-dione
1,4-dihydroxyanthraquinone, purum, >=98.0% (hplc), powder, red-brown
4,9-dihydroxy-1,10-anthraquinone
quinizarin; 1,4-dihydroxyanthraquinone
AS-14244
Q906609
1,4-dihydroxy-9,10-anthraquinone; 1,4-dihydroxyanthraquinone; smoke orange r; quinizarine
EN300-6486266
CS-0010138
HY-D0226
F87345

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Data on natural toxic chemicals could be used for extrapolation methods such as read-across."( The comparative toxicity to soil invertebrates of natural chemicals and their synthetic analogues.
Chaplow, JS; Harman, M; Hopkin, S; Potter, E; Scott, WA; Sims, I; Sorokin, N; Whitaker, J, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
dyenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dihydroxyanthraquinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency79.43280.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency39.42610.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency30.89560.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency30.89560.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency24.33650.000714.592883.7951AID1259369
Microtubule-associated protein tauHomo sapiens (human)Potency8.06030.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency17.47220.000221.22318,912.5098AID1259243; AID1259247; AID743036
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency54.48270.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency28.06340.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency22.77790.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.22630.001530.607315,848.9004AID1224841; AID1224842; AID1259401
farnesoid X nuclear receptorHomo sapiens (human)Potency7.76060.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency4.85580.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.49380.000229.305416,493.5996AID743069
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency27.53570.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency19.49380.001019.414170.9645AID743094
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency24.54120.023723.228263.5986AID743222
aryl hydrocarbon receptorHomo sapiens (human)Potency5.93030.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency48.55770.001723.839378.1014AID743083
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency6.85900.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency5.36380.000627.21521,122.0200AID743202; AID743219
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency21.68990.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency21.68990.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thioredoxin reductase 1, cytoplasmicRattus norvegicus (Norway rat)IC50 (µMol)200.00000.27201.82606.0000AID551520
TransthyretinHomo sapiens (human)IC50 (µMol)100.00000.16004.292110.0000AID1755162
DNA topoisomerase 2-alphaHomo sapiens (human)IC50 (µMol)200.00000.48004.35649.9400AID1524651; AID1524652; AID1524653; AID1524654; AID1524655; AID1524656
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)0.06500.00002.37899.7700AID1888748
Amine oxidase [flavin-containing] AHomo sapiens (human)Ki0.03900.00192.379710.0000AID1888753
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)110.00000.00001.89149.5700AID1888749
Casein kinase I isoform alphaHomo sapiens (human)IC50 (µMol)40.00000.00102.249910.0000AID387940
Casein kinase I isoform deltaHomo sapiens (human)IC50 (µMol)40.00000.00401.127210.0000AID387938
DNA topoisomerase 2-betaHomo sapiens (human)IC50 (µMol)200.00000.03002.77167.8000AID1524651; AID1524652; AID1524653; AID1524654; AID1524655; AID1524656
Casein kinase I isoform gamma-1Homo sapiens (human)IC50 (µMol)40.00000.00404.71639.5000AID387939
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (88)

Processvia Protein(s)Taxonomy
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
protein phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
Golgi organizationCasein kinase I isoform alphaHomo sapiens (human)
cell surface receptor signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
viral protein processingCasein kinase I isoform alphaHomo sapiens (human)
cellular response to nutrientCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of Rho protein signal transductionCasein kinase I isoform alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
intermediate filament cytoskeleton organizationCasein kinase I isoform alphaHomo sapiens (human)
cell divisionCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of TORC1 signalingCasein kinase I isoform alphaHomo sapiens (human)
signal transductionCasein kinase I isoform alphaHomo sapiens (human)
microtubule nucleationCasein kinase I isoform deltaHomo sapiens (human)
Golgi organizationCasein kinase I isoform deltaHomo sapiens (human)
protein localization to Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
protein localization to ciliumCasein kinase I isoform deltaHomo sapiens (human)
protein localization to centrosomeCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform deltaHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform deltaHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform deltaHomo sapiens (human)
COPII vesicle coatingCasein kinase I isoform deltaHomo sapiens (human)
spindle assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
midbrain dopaminergic neuron differentiationCasein kinase I isoform deltaHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
signal transductionCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
endocytosisCasein kinase I isoform deltaHomo sapiens (human)
neuron migrationDNA topoisomerase 2-betaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-betaHomo sapiens (human)
axonogenesisDNA topoisomerase 2-betaHomo sapiens (human)
B cell differentiationDNA topoisomerase 2-betaHomo sapiens (human)
forebrain developmentDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to hydrogen peroxideDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to ATPDNA topoisomerase 2-betaHomo sapiens (human)
cellular senescenceDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA topoisomerase 2-betaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-betaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-betaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-1Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-1Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-1Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-1Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
protein kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein bindingCasein kinase I isoform alphaHomo sapiens (human)
ATP bindingCasein kinase I isoform alphaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein bindingCasein kinase I isoform deltaHomo sapiens (human)
ATP bindingCasein kinase I isoform deltaHomo sapiens (human)
cadherin bindingCasein kinase I isoform deltaHomo sapiens (human)
tau-protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-betaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-betaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-betaHomo sapiens (human)
protein bindingDNA topoisomerase 2-betaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complex bindingDNA topoisomerase 2-betaHomo sapiens (human)
metal ion bindingDNA topoisomerase 2-betaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-1Homo sapiens (human)
protein bindingCasein kinase I isoform gamma-1Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-1Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (41)

Processvia Protein(s)Taxonomy
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mRNA cleavage and polyadenylation specificity factor complexCasein kinase I isoform alphaHomo sapiens (human)
keratin filamentCasein kinase I isoform alphaHomo sapiens (human)
kinetochoreCasein kinase I isoform alphaHomo sapiens (human)
centrosomeCasein kinase I isoform alphaHomo sapiens (human)
spindleCasein kinase I isoform alphaHomo sapiens (human)
cytosolCasein kinase I isoform alphaHomo sapiens (human)
ciliumCasein kinase I isoform alphaHomo sapiens (human)
membraneCasein kinase I isoform alphaHomo sapiens (human)
nuclear speckCasein kinase I isoform alphaHomo sapiens (human)
beta-catenin destruction complexCasein kinase I isoform alphaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform alphaHomo sapiens (human)
cytoplasmCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
nucleoplasmCasein kinase I isoform deltaHomo sapiens (human)
Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
centrosomeCasein kinase I isoform deltaHomo sapiens (human)
spindleCasein kinase I isoform deltaHomo sapiens (human)
cytosolCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
plasma membraneCasein kinase I isoform deltaHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneCasein kinase I isoform deltaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform deltaHomo sapiens (human)
perinuclear region of cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
heterochromatinDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-betaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
cytosolDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
cytosolCasein kinase I isoform gamma-1Homo sapiens (human)
nucleusCasein kinase I isoform gamma-1Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-1Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (71)

Assay IDTitleYearJournalArticle
AID1178081Cytotoxicity against human ChaGo cells at 10 uM after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Anthracene-9, 10-dione derivatives induced apoptosis in human cervical cancer cell line (CaSki) by interfering with HPV E6 expression.
AID39252Inhibitory concentration against B16 murine melanoma cell line2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID285172Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 5 ug/ml relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID80256Inhibitory concentration against HCT 116 human colon cancer cell line2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID687632Binding affinity to calf thymus DNA in Brittone-Robinson buffer at 50 uM by UV-vis spectroscopy in presence of denatured DNA2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID336955Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID8620Inhibitory concentration required against A 431 human epidermoid carcinoma cell line2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Syntheses of certain 3-aryl-2-propenoates and evaluation of their cytotoxicity.
AID1178078Cytotoxicity against human HepG2 cells at 10 uM after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Anthracene-9, 10-dione derivatives induced apoptosis in human cervical cancer cell line (CaSki) by interfering with HPV E6 expression.
AID336956Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID387940Inhibition of CK1alpha2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening.
AID1178079Cytotoxicity against human CaSki cells at 10 uM after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Anthracene-9, 10-dione derivatives induced apoptosis in human cervical cancer cell line (CaSki) by interfering with HPV E6 expression.
AID285171Activity against planktonic Streptococcus mutans LMG 145582007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID1178080Cytotoxicity against human KATO III cells at 10 uM after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Anthracene-9, 10-dione derivatives induced apoptosis in human cervical cancer cell line (CaSki) by interfering with HPV E6 expression.
AID463423Cytotoxicity against human A549 cells at 500 ug/ml2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis of glycoside derivatives of hydroxyanthraquinone with ability to dissolve and inhibit formation of crystals of calcium oxalate. Potential compounds in kidney stone therapy.
AID1888749Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID687628Binding affinity to calf thymus DNA in Brittone-Robinson buffer at 50 uM at pH 7 in presence of NaCl by UV-vis spectroscopy2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID1178073Cytotoxicity against human CaSki cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Anthracene-9, 10-dione derivatives induced apoptosis in human cervical cancer cell line (CaSki) by interfering with HPV E6 expression.
AID1524652Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1524654Inhibition of topoisomerase 2 in human CNE1 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID102410Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 10 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID336954Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID251357Antifilarial activity against Brugia malayi (female) at 5 ppm in the first 5 days (100% mortality)2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Synthesis and activity of substituted anthraquinones against a human filarial parasite, Brugia malayi.
AID336958Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID687633Binding affinity to calf thymus DNA at 50 uM by circular dichroism spectra2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID463421Induction of calcium oxalate dissolution assessed as increase in calcium concentration after 5 days by flame photometry relative to untreated control2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis of glycoside derivatives of hydroxyanthraquinone with ability to dissolve and inhibit formation of crystals of calcium oxalate. Potential compounds in kidney stone therapy.
AID1524657Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID251352Antifilarial activity against Microfilaria at 5 ppm in the first 5 days (100% mortality)2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Synthesis and activity of substituted anthraquinones against a human filarial parasite, Brugia malayi.
AID687631Binding affinity to calf thymus DNA in Brittone-Robinson buffer at 50 uM by UV-vis spectroscopy in presence of native DNA2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID463424Cytotoxicity against mouse L929 cells at 500 ug/ml2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis of glycoside derivatives of hydroxyanthraquinone with ability to dissolve and inhibit formation of crystals of calcium oxalate. Potential compounds in kidney stone therapy.
AID1888748Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1888753Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by Lineweaver-Burk plot analysis2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID687629Binding affinity to calf thymus DNA in Brittone-Robinson buffer at 50 uM at pH 7 by by UV-vis spectroscopy2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID336960Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio
AID687637Ratio of danthron Kb to quinizarin Kb for calf thymus DNA2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID687630Binding affinity to calf thymus DNA in Brittone-Robinson buffer at 50 uM at pH 3 by UV-vis spectroscopy2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID251355Antifilarial activity against Brugia malayi (male) at 5 ppm in the first 5 days (NT=Not Tested)2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
Synthesis and activity of substituted anthraquinones against a human filarial parasite, Brugia malayi.
AID335923Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of ADP-stimulated platelet aggregation pretreated 2 mins before ADP challenge
AID336959Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio
AID687635Binding affinity to calf thymus DNA assessed as hydrogen bonding2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID551520Inhibition of rat liver cytosolic TrxR1 by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID336953Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID463422Induction of surgically removed human kidney stone dissolution assessed as increase in calcium concentration after 5 days by flame photometry relative to untreated control2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis of glycoside derivatives of hydroxyanthraquinone with ability to dissolve and inhibit formation of crystals of calcium oxalate. Potential compounds in kidney stone therapy.
AID1524655Inhibition of topoisomerase 2 in human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1524651Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID336957Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio
AID387938Inhibition of CK1delta2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening.
AID387939Inhibition of CK1gamma12008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening.
AID102409Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 1 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID335922Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of arachidonic acid-stimulated platelet aggregation pretreated 2 mins before arachidonic acid challenge
AID687634Binding affinity to calf thymus DNA at DNA/compound ratio 0.1 to 2 at pH 7 by measuring DNA viscosity2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID687636Binding affinity to calf thymus DNA assessed as partial intercalation2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID335924Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of collagen-stimulated platelet aggregation pretreated 2 mins before collagen challenge
AID102411Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 3 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID1524656Inhibition of topoisomerase 2 in human MDA-MB-231 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1178082Cytotoxicity against human SW620 cells at 10 uM after 72 hrs by MTT assay2014European journal of medicinal chemistry, Apr-22, Volume: 77Anthracene-9, 10-dione derivatives induced apoptosis in human cervical cancer cell line (CaSki) by interfering with HPV E6 expression.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1755162Inhibition of acid-mediated aggregation of TTR V30M mutant (unknown origin) expressed in Escherichia coli pretreated for 30 mins at pH 7 followed by protein dilution in acetate buffer and further incubated for 96 hrs at pH 4.6 by thioflavin-T fluorescence2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID551521Inhibition of rat liver mitochondrial TrxR2 by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID1524653Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1888750Selectivity index, ratio IC50 for recombinant human MAO-B to IC50 for recombinant human MAO-A2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID463420Inhibition of calcium oxalate crystal formation assessed as change of shift in titration end point by conductometric titration2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis of glycoside derivatives of hydroxyanthraquinone with ability to dissolve and inhibit formation of crystals of calcium oxalate. Potential compounds in kidney stone therapy.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (6.35)18.7374
1990's4 (6.35)18.2507
2000's13 (20.63)29.6817
2010's32 (50.79)24.3611
2020's10 (15.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.36 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index5.06 (4.65)
Search Engine Demand Index33.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other63 (96.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]